Page 4 - Dr Lal Pathlabs

Thyrocare, Dr Lal PathLabs: Healthcare stocks can rally more, charts show

A new all time high shows bullish sentiment is here to stay in these stocks.

Healthcare services stocks rally; Thyrocare up 35% in 2 days post Q2 update

Thyrocare Technologies, Metropolis Healthcare and Dr. Lal PathLabs, hitting their respective record highs, were up 9 per cent to 17 per cent on the BSE in intra-day trade.

Two pharma stocks that Ajit Mishra of Religare Broking is bullish on

All indicators point to a gradual rise in Aurobindo Pharma's stock from the 100 EMA support

Margin pressures likely to cap upside for Dr Lal Pathlabs: Analysts

The 29 per cent fall in volumes in the quarter was responsible for revenues declining 21 per cent year-on-year

Margin pressures to cap upside for Dr Lal Pathlabs as Covid dents volumes

Valuations too do not leave much scope for gains

Dr Lal PathLabs June quarter net profit declines 52% to Rs 28.4 crore

Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.

Healthcare services stocks in focus; Dr Lal PathLabs, Thyrocare up over 5%

Metropolis Healthcare, meanwhile, rallied 7% to Rs 1,579 today, and were trading higher for the eighth straight day

Neuberg Diagnostics starts Covid-19 testing at its Chennai laboratory

Firm will be scaling up its capacity up to 2,000-2,500 tests a day as per ICMR norms by next week

Thyrocare Tech, Dr Lal Path Labs surge as pvt labs to conduct Covid-19 test

That apart, national laboratories have also been allowed to carry out clinical testing of Covid-19, as the number of cases went past 400 in India.

Kiran Mazumdar-Shaw wins EY Entrepreneur of the Year award for 2019

Awards announced for nine other categories; Adi Godrej gets Lifetime achievement award

Metropolis Healthcare leads diagnostics pack on higher realisation

Expansion, raising share of B2C network to help improve margins

Diagnostic players ride on changes in health insurance to beat slowdown

Metropolis, Dr Lal and Thyrocare are likely to see more gains led by expansion, increasing penetration, preventive testing and government's Ayushman Bharat scheme

Volume growth key to Dr Lal Pathlab's health; stock rises over 4%

Firm banking on acquisitions, and rationalisation of prices

Dr Lal PathLabs to buy 70% stake in a new firm to strengthen presence in MP

Dr Lal PathLabs' board has approved the signing a binding term sheet for the acquisition

Dr Lal PathLabs reports 12.8% jump in net profit at Rs 574 million

Operating margin declined to 28.5 per cent as against 29 per cent a year ago

Dr. Lal PathLabs surges 16% on strong Q4 results

The stock surged 16% to Rs 931, also its 52-week high on the BSE in intra-day trade after the company reported a better than expected 27% YoY growth in net profit at Rs 402 million in Q4FY18.

Q1 results: Dr Lal PathLabs' health improves

Better margins and focus on cost rationalisation to drive earnings

Dr Lal PathLabs: Street worried over rising pressures

The stock of Dr Lal Pathlabs fell 6.4 per cent after brokerages cut their margins and earnings estimates sharply for the company due to rising pressures on pricing and volumes. Morgan Stanley, which has cut its target price to Rs 700 from Rs 888, believes that the company will face substantial pressure on both pricing and volumes given competitive intensity. Some of the pressures were visible in the March quarter performance, which saw the company's operating profit margins decline 298 basis points year-on-year to 23.6 per cent.Competition in the business-to-business (B2B) segment, promotional and employee expenses as well as costs associated with setting up new labs, added to the pressure. The B2B segment, which includes revenues from nursing homes and hospitals among others, accounts for 40 per cent of the company's revenues. Going ahead, analysts at Nomura believe that the company's operating profit margins could be under pressure and could contract 100 to 200 basis points given ...

Dr Lal PathLabs hits 52-week low after block deals

The stock slipped 6.5% to Rs 780 after two per cent of total equity changed hands on NSE and BSE.

Dr Lal PathLabs eyes growth via acquisitions

Dr Lal PathLabs is focusing on 'inorganic growth'